TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00669487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
Study: NCT03331653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling and Ischemic Compression at the Trigger Point
Description: The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
Description: The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
Study: NCT01241552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3415
Description: A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6072
Description: A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3415A
Description: A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IV infusion of normal saline (0.9% sodium chloride)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study: NCT00908063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycyte
Description: A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
Study: NCT04004429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AP1189
Description: 50 mg AP1189 powder in bottle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189
Description: 100 mg AP1189 powder in bottle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder in bottle
Study: NCT00912652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Three doses of lifestyle intervention will be compared to an education control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Three doses of lifestyle intervention will be compared to an education control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Three doses of lifestyle intervention will be compared to an education control condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
Study: NCT03631745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAMI Mental Health 101 and NAMI FaithNet
Description: Congregants of Intervention Churches will receive:~1. NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~2. NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families.
Study: NCT01526551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV Vaccine and HPV-related Health Education
Description: Increased education of HPV-related diseases and HPV vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of barriers
Description: Eliminate structural and financial barriers to being vaccinated
Study: NCT04589182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHSL- SleepBand
Description: The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
Study: NCT01200108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Study: NCT02939872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin and clopidogrel
Description: at the discretion of investigator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel only
Description: at the discretion of investigator
Study: NCT04111965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanodrop®
Description: minimum to meet 1 drop 4 times a day, both eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Balance
Description: minimum to meet 1 drop 4 times a day, both eyes
Study: NCT02740296

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT01919320

Intervention type: DEVICE
Intervention: C2 Driver System TAH-t Patients
Description: Comparison of two pneumatic drivers supporting the SynCardia TAH-t

Intervention type: DEVICE
Intervention: C2 Driver System TAH-t Patients
Description: Comparison of two pneumatic drivers supporting the SynCardia TAH-t

Intervention type: DEVICE
Intervention: CSS Console TAH-t Patients
Description: Comparison of two pneumatic drivers supporting the SynCardia TAH-t.

Intervention type: DEVICE
Intervention: CSS Console TAH-t Patients
Description: Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
Study: NCT02540863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release protocol and Rocabado exercise therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Study: NCT01622179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sewed indirectly
Description: The epitenon was repaired and sewed indirectly.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sewed directly
Description: The epitenon was unrepaired and sewed directly.
Study: NCT04225468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACL Opioid Exposure Reduction Program
Description: Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACL Opioid Exposure Reduction Program
Description: Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
Study: NCT03971656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Oral nutritional supplementation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Dietitian Consult
Description: Nutritional assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Informational materials about nutrition
Study: NCT02251925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: frozen Embryo transfer
Description: In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: frozen Embryo transfer
Description: In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: frozen Embryo transfer
Description: In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: frozen Embryo transfer
Description: In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10,000U hCG injection
Description: In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist (Superfact)
Description: In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of 6 mg Estradiol valerate
Description: In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
Study: NCT02906345

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Plasma Exchange (TPE)
Description: All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Plasma Exchange (TPE)
Description: All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
Study: NCT01617850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise training x3 weekly for 12 weeks
Description: Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical exercise training x2 weekly for 8 weeks
Description: Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
Study: NCT01558583

Intervention type: OTHER
Group type: OTHER
Intervention: Rating and Ranking Task
Description: Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Discrete Choice Task
Description: Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.

Intervention type: OTHER
Group type: OTHER
Intervention: Balance Sheet Task
Description: Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
Study: NCT01088191

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSB-CAR001 Combined With Hyaluronan
Description: Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSB-CAR001 Combined With Hyaluronan
Description: Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronan
Description: Hyaluronan alone
Study: NCT00931944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNS-760704
Description: 150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
Study: NCT03858452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscles exercises program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscles exercises program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscles exercises program
Study: NCT02564107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
Study: NCT00239226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IAS pacing - study group
Description: site of implant and permanent pacing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IAS pacing control group
Description: site of implant and permanent pacing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing RAA study group
Description: site of implant and permanent pacing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing RAA control group
Description: site of implant and permanent pacing
Study: NCT02225717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervicovaginal swab
Description: Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervicovaginal swab
Description: Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervicovaginal swab
Description: Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
Study: NCT02236884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-scar transanal total mesorectal excision(TME)
Study: NCT02187614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Study: NCT04653168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered SC
Study: NCT02939755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Description: Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: usual care from health providers
Study: NCT00800787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nabi-HB
Description: Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML \> 75 Kg: 1,000 IU weekly
Study: NCT00762749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine HCl
Description: A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
Study: NCT02094833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T combined vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T and Hepatitis B vaccine
Description: 0.5 mL, Intramuscular
Study: NCT00578786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: 2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
Study: NCT00162890

Intervention type: BEHAVIORAL
Intervention: Therapeutic exercise
Study: NCT03463733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
Study: NCT06226831

Intervention type: OTHER
Intervention: Structured interview
Description: In-person structured interviews will be performed by the investigators.

Intervention type: OTHER
Intervention: Structured interview
Description: In-person structured interviews will be performed by the investigators.